---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009124"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T20:43:56.754544+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter

## Summary
- Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.
- Net loss $15.6M (increase 124% YoY); operating expenses $17.8M, up 10%.
- Raised $27.4M post-Q1: $11.7M private placement, $2.7M ATM, $13M net from $25M debt facility.
- Restructured Indi milestone payments, reducing 2022 pay by $7.5M and 2023 by $7.2M.
- Reaffirmed FY2022 total revenue outlook of $37.5M-$39.5M.

## SEC filing metadata
- accession: 0000950170-22-009124
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/0000950170-22-009124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/bdsx-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009124
- JSON: https://secwatch.observer/filing/0000950170-22-009124.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.